Padmanabha Shenoy

Dr. Padmanabha Shenoy


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2020 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
PSPadmanabha Shenoy
Padmanabha Shenoy
SASakir Ahmed
Sakir Ahmed
APAby Paul
Aby Paul
TSTeny Grace Skaria
Teny Grace Skaria
JJJoel Joby
Joel Joby
BABazil Alias
Bazil Alias
The emergent COVID-19 pandemic dictates an urgent switch to teleconsultation. India has high patient to rheumatologist ratio, and patients have limited concepts about telemedicine. Thus, we attempted to find the feasibility and acceptance of patients in switching to teleconsultation. The CARE rheumatology clinic at Kerala, India, caters to average 170 (range: 140–240) patients per day. Patients with prefixed appointments had two-level screening for eligibility for teleconsultation. Those eligible were given the option for teleconsultation on the widely available WhatsApp app. Of those who completed teleconsultations, 100 were chosen at random to provide feedback. In the first 7 days, out of 1469 appointments, 975 were found eligible for teleconsultation. Of these, 723 (74%) opted for it. The average footfall in the clinic was reduced to 67 (range 29–117). The proportion of patients accepting teleconsultations increased with time. Amongst the 100 respondents, median satisfaction was 9 (IQR 8–10) and recommendation for continuing was 9.5 (IQR 8–10) on a 0–10 scale. Multivariate analysis showed the recommendation score was dependent on beliefs about social distancing, perceptions about clinical examination, and the satisfaction score of the first teleconsultation. Age, sex, availability of personal video conferencing app or of vehicles did not independently influence this score. Without teleconsultation facilities, three-fourths of the respondents would have stopped drugs or self-medicated. The switch was feasible and accepted by patients. It enabled quick reduction in the number of persons travelling to the centre. Not making the switch could have deprived approximately three-quarters of these patients of proper medical care. Key Points • Patient to rheumatologist ratios in India is heavily skewed and awareness about telemedicine is limited. • Switch to telemedicine was feasible and allowed a decrease in the number of people attending the clinic. • Not switching could have lead to disruption of care or self-medication in a majority of patients.

8 February 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
SASakir Ahmed
Sakir Ahmed
PMPankti Mehta
Pankti Mehta
APAby Paul
Aby Paul
SAS Anu
S Anu
SCSomy Cherian
Somy Cherian
PSPadmanabha Shenoy
Padmanabha Shenoy
Introduction To assess the incidence and risk factors for breakthrough COVID-19 infection in a vaccinated cohort of patients with autoimmune rheumatic diseases (AIRDs) and determine whether antibodies to receptor binding domain of spike protein (anti-RBD) serve as a reliable predictor of susceptibility to such infections. Methods Patients with AIRDs who had completed two doses of SARS-CoV2 vaccines were included and anti-RBD antibodies were determined 4–6 weeks post the second vaccine dose and stratified into good responders (GR) (>212 IU), inadequate responders (IR) (0.8–212 IU) and non-responders (NR) (<0.8 IU). Patients who had completed a minimum of 8 weeks interval after the second dose of vaccine were followed up every 2 months to identify breakthrough infections. All sero converted patients who had contact with COVID-19 were also analysed for neutralising antibodies. Results We studied 630 patients of AIRDs (mean age 55.2 (±11.6) years, male to female ratio of 1:5.2). The majority of patients had received AZD1222 (495, 78.6%) while the remaining received the BBV152 vaccine. The mean antibody titre was 854.1 (±951.9), and 380 (60.3%) were GR, 143 (22.7%) IR and 107 (16.9%) NR. Breakthrough infections occurred in 47 patients (7.4%) at a mean follow-up of 147.3 (±53.7) days and were proportionately highest in the NR group (19; 17.75%), followed by the IR group (13; 9.09%) and least in the GR group (15; 3.95%). On log-rank analysis, antibody response (p<0.00001), vaccine(p=0.003) and mycophenolate mofetil (p=0.007) were significant predictors of breakthrough infections. On multivariate Cox regression, only NR were significantly associated with breakthrough infections (HR: 3.6, 95% CI 1.58 to 8.0, p=0.002). In sero converted patients with contact with COVID-19, neutralisation levels were different between those who developed and did not develop an infection. Conclusion Breakthrough infections occurred in 7.4% of patients and were associated with seronegativity following vaccination. This provides a basis for exploring postvaccination antibody titres as a biomarker in patients with AIRD.

17 June 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
SCSomy Cherian
Somy Cherian
APAby Paul
Aby Paul
SASakir Ahmed
Sakir Ahmed
BABazil Alias
Bazil Alias
MMManesh Manoj
Manesh Manoj
PSPadmanabha Shenoy
Padmanabha Shenoy

2 June 2016 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
PSPadmanabha Shenoy
Padmanabha Shenoy
MBManish Bavaliya
Manish Bavaliya
SSSujith Sashidharan
Sujith Sashidharan
KNKaveri Nalianda
Kaveri Nalianda
SSSreelakshmi Sreenath
Sreelakshmi Sreenath
Scleroderma is a systemic autoimmune disease characterized mainly by skin manifestations and involvement of various visceral organs, especially the lungs. Lung involvement is the leading cause of mortality in patients with scleroderma. There are data to suggest that cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are effective in the management of scleroderma interstitial lung disease (SSc-ILD) but no head to head comparative data are available to date. For the last 3 years, patients with SSc-ILD have been treated at our centre by protocol-based administration of intravenous CYC and MMF. Results of lung function tests (spirometry) were recorded at baseline, 3 months and 6 months in every patient. The clinical records of patients with systemic sclerosis and significant ILD, who were not previously exposed to any immunosuppressant and were treated with MMF OR CYC, were reviewed. The efficacy of treatment was assessed by the change in forced vital capacity on spirometry. Of the total 57 patients included in the analysis, 34 were treated with MMF and 23 were treated with CYC. Mean duration of illness was 4.19 ± 2.82 years in the MMF and 6.04 ± 5.96 years in the CYC group. After 6 months of therapy, FVC increased by 10.84 ± 13.81 % in the CYC group and by 6.07 ± 11.92 % in the MMF group. This improvement from baseline was statistically significant in both groups (P < 0.01). The improvement was comparable with no statistically significant differences between groups (P = 0.373). There were no major adverse events reported in either arm. Both MMF and CYC were equally effective in stabilizing lung function in patients with scleroderma and ILD.

1 May 2010 in Autoimmunity Reviews
Verified
Journal Article
Closed access
PSPadmanabha Shenoy
Padmanabha Shenoy
VAVikas Agarwal
Vikas Agarwal

12 September 2022 in The Lancet Rheumatology
Verified
Journal Article
Closed access
TSTeny Grace Skaria
Teny Grace Skaria
ASAnu Sreeprakash
Anu Sreeprakash
RURashwith Umesh
Rashwith Umesh
SJSneha Joseph
Sneha Joseph
MMManju Mohan
Manju Mohan
PSPadmanabha Shenoy
Padmanabha Shenoy